Search research articles
Contact Us
Filters
Showing results (211-220 of 218) with videos related to
Page
of 22
Sort By:
You have reached the last page of results.
This site can display upto 218 results.
Oncogene
|
August 28, 2024
S-p-bromobenzyl-glutathione cyclopentyl diester (BBGC) as novel therapeutic strategy to enhance trabectedin anti-tumor effect in soft tissue sarcoma preclinical models
F Pantano, S Simonetti, M Iuliani, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 20, 2014
Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial
F Ciardiello, N Normanno, E Maiello, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 23, 2016
Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX
F Ciardiello, N Normanno, E Martinelli, et al.
Journal of Bone Oncology
|
July 26, 2018
Bone metastases in biliary cancers: A multicenter retrospective survey
D Santini, G Brandi, G Aprile, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 6, 2012
Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study
D Santini, M Tampellini, B Vincenzi, et al.
ESMO Open
|
August 30, 2017
Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial
E Martinelli, C Cardone, T Troiani, et al.
NPJ Precision Oncology
|
April 10, 2026
The role of the molecular tumor board: learnings from the ROME trial
P Marchetti, G Curigliano, C B Westphalen, et al.
ESMO Gastrointestinal Oncology
|
May 22, 2026
Baseline neutrophil-to-eosinophil ratio and neutrophil-to-lymphocyte ratio as prognostic markers in patients with unresectable biliary tract cancer treated with gemcitabine-cisplatin-durvalumab: an international, multicentre, retrospective cohort study
H Vandeputte, A Casadei-Gardini, F Peeters, et al.
Page
of 22
Search research articles
Search
Showing results (211-220 of 218) with videos related to
Sort By:
Page
of 22
You have reached the last page of results.
This site can display upto 218 results.
Oncogene
|
August 28, 2024
S-p-bromobenzyl-glutathione cyclopentyl diester (BBGC) as novel therapeutic strategy to enhance trabectedin anti-tumor effect in soft tissue sarcoma preclinical models
F Pantano, S Simonetti, M Iuliani, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 20, 2014
Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial
F Ciardiello, N Normanno, E Maiello, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 23, 2016
Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX
F Ciardiello, N Normanno, E Martinelli, et al.
Journal of Bone Oncology
|
July 26, 2018
Bone metastases in biliary cancers: A multicenter retrospective survey
D Santini, G Brandi, G Aprile, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 6, 2012
Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study
D Santini, M Tampellini, B Vincenzi, et al.
ESMO Open
|
August 30, 2017
Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial
E Martinelli, C Cardone, T Troiani, et al.
NPJ Precision Oncology
|
April 10, 2026
The role of the molecular tumor board: learnings from the ROME trial
P Marchetti, G Curigliano, C B Westphalen, et al.
ESMO Gastrointestinal Oncology
|
May 22, 2026
Baseline neutrophil-to-eosinophil ratio and neutrophil-to-lymphocyte ratio as prognostic markers in patients with unresectable biliary tract cancer treated with gemcitabine-cisplatin-durvalumab: an international, multicentre, retrospective cohort study
H Vandeputte, A Casadei-Gardini, F Peeters, et al.
Page
of 22